NUCLEAR MEDICINE: Discovery™ NM/CT 670 Pro

Leading Clinical Discovery with Hybrid Imaging.

NUCLEAR MEDICINE: Discovery™ NM/CT 670 Pro

Leading Clinical Discovery with Hybrid Imaging.

With our latest CT technology, the Discovery NM/CT 670 Pro helps you obtain excellent image quality, to explore the deepest regions where disease arises and see beyond what once was thought possible.

Watch the Video

Fast Facts

  • Standalone CT capabilities
    • Tube Power
    • Protocol flexibility
    • Dose reduction technologies

  • Nuclear Medicine

    Evolution1: Up to 50% dose reduction
    • Evolution for Bone* and Bone SPECT**
    • Evolution for Cardiac***

    Improve visual clarity with:
    • Evolution Toolkit – Tl201, Ga67, I123, In111 SPECT

  • Q.Metrix application utilizes advanced Evolution reconstruction with compensation for Attenuation, Resolution and Scatter.
    Quantitative SPECT results are further enhanced with advance segmentation tools providing 2D and 3D organ and lesion characterization.

  • Q.AC

    Attenuation Correction with Q.AC, reconstructed low dose CTAC provides more accurate correction5, enabling SPECT quantitative accuracy.5

  • Computed Tomography

    • ASiR™2,3: Significant CT dose reduction
    • Q.AC: 5 mAs accurate attenuation correction4,5
    • IQE: 70 cm anatomy coverage in 10 seconds
    • Compliant with MITA XR-296

Discovery is a trademark of General Electric Company.
* Compared to standard Bone Planar protocol, option on D670Pro
** Compared to standard Bone SPECT protocol, option on D670Pro
*** Compared to standard MPI protocol, option on D670Pro
1 Evolution Disclaimer In clinical practice, Evolution options3a (Evolution for Bone, Evolution for Cardiac, Evolution for Bone Planar) and Evolution Toolkit3b are recommended for use following consultation of a NM physician, physicist and/or application specialist to determine the appropriate dose or scan time reduction to obtain diagnostic image quality for a particular clinical task, depending on the protocol adopted by the clinical site.
3aEvolution Options tags - Evolution claims are supported by simulation of count statistics using default factory protocols and imaging of 99mTc based radiotracers with LEHR collimator on anthropomorphic phantom or realistic NCAT – SIMSET phantom followed by quantitative and qualitative images comparison.
3bEvolution Toolkit tag - Evolution Toolkit claims are supported by simulation of full count statistics using lesion simulation phantom images based on various radiotracers and collimators and by showing that SPECT image quality reconstructed with Evolution Toolkit provide equivalent clinical information but have better signal-to-noise, contrast, and lesion resolution compared to the images reconstructed with FBP / OSEM.
2 ASiR is an optional feature in the Discovery NM/CT 670 Pro.
3 In clinical practice, the use of ASiR may reduce CT patient dose depending on the clinical task, patient size, anatomical location and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task.
4 Compared to same study reconstructed w/o Q.AC.
5 Quantitative accuracy defined as equivalence to well-counter-measured injected activity in the test phantom. (Equivalence means <5% difference when comparing measured counts in SPECT studies corrected by Q.AC-reconstructed CTAC to measured counts in studies corrected by benchmark-reconstructed CTAC. Measured counts are defined as average within identical ROI’s positioned on SPECT-reconstructed slices of homogenous 99mTc solution phantom study.

Contact us